Phenotypic variations and new mutations in JAK2 V617F–negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis
- 30 November 2007
- journal article
- Published by Elsevier BV in Experimental Hematology
- Vol. 35 (11), 1641-1646
- https://doi.org/10.1016/j.exphem.2007.08.010
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraBlood, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisNew England Journal of Medicine, 2007
- Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expressionBlood, 2006
- MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patientsPublished by American Society of Hematology ,2006
- MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid MetaplasiaPLoS Medicine, 2006
- The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia veraCancer, 2005
- Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersBlood, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005